InVision Precision Cardiac Amyloid vs EchoNext

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 75/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

InVision Precision Cardiac Amyloid

by InVision Medical Technology Corporation

EchoNext

by Pathway Labs

AI Verdict

Both tools leverage AI for cardiac disease detection, but they differ in their primary diagnostic input and specific focus. InVision Precision Cardiac Amyloid specializes in analyzing echocardiograms for cardiac amyloidosis, while EchoNext analyzes standard ECGs to detect a broader range of hidden structural heart diseases. Therefore, the choice depends on whether the clinical need is for specialized amyloidosis detection via echocardiography or broader structural heart disease screening via ECG.

Choose InVision Precision Cardiac Amyloid if…

Choose InVision Precision Cardiac Amyloid if your echocardiography lab focuses on specialized cardiac imaging and aims for early, precise detection of cardiac amyloidosis. This AI-powered software integrates directly into existing echocardiography workflows, analyzing transthoracic echocardiogram studies to aid clinicians in diagnosing both AL and ATTR Cardiac Amyloidosis, even before heart failure symptoms appear.

View InVision Precision Cardiac Amyloid →

Choose EchoNext if…

Choose EchoNext if your practice seeks a broad, accessible, and non-invasive screening tool for hidden structural heart disease using standard ECGs. This FDA-cleared AI tool can identify risks for conditions like heart failure, valve disease, and pulmonary hypertension, making it ideal for widespread screening in various clinical settings, from major hospitals to community practices.

View EchoNext →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	InVision Precision Cardiac Amyloid	EchoNext
Pricing	Subscription	Starts at $600/month
Deployment	Software as a Medical Device (SaMD), integrated into clinical workflows for echocardiography labs.	Available through the OpenEvidence clinical decision support platform.
BAA Available	Unknown	Yes AI-estimated
FDA Status	1 AI-estimated	Yes AI-estimated
HIPAA	Unknown	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

InVision Precision Cardiac Amyloid

InVision Precision Cardiac Amyloid is designed to integrate into existing clinical workflows for echocardiography labs, aiming to streamline interpretation and standardize measurements. It also flags patients at high suspicion for cardiac amyloidosis for further consideration by clinicians, reducing manual effort.

Clinical Value

EchoNext

EchoNext detects a broader range of structural heart diseases (six indications, including heart failure, valve disease, and pulmonary hypertension) from a routine ECG, which is a widely available and inexpensive test. In contrast, InVision Precision Cardiac Amyloid focuses specifically on cardiac amyloidosis detection from echocardiograms.

Pricing & Value

InVision Precision Cardiac Amyloid

InVision Precision Cardiac Amyloid offers a clear starting subscription price of $49/month, with enterprise pricing available. EchoNext's starting price is significantly higher at $600/month, and while it offers tiered pricing, the base cost is substantially more.

Enterprise Readiness

InVision Precision Cardiac Amyloid

InVision Precision Cardiac Amyloid has FDA 510(k) clearance, Breakthrough Device Designation, and is enrolled in the FDA's Total Product Lifecycle Advisory Program (TAP). It also has a CPT Category III code (0932T) effective January 1, 2025, supporting a direct reimbursement path, which is crucial for enterprise adoption. EchoNext also has FDA clearance and has secured an $8.5 million seed financing round to support expansion across health systems.

Innovation

EchoNext

EchoNext is highlighted as the world's first FDA-cleared AI tool for detecting hidden structural heart disease from standard ECGs, covering six different conditions. This broad detection from a widely accessible test represents a significant innovative leap in early cardiac screening.

Support & Docs

Tie

Both tools are FDA-cleared and have published clinical validation studies, indicating a commitment to scientific rigor and transparency. However, specific details regarding ongoing customer support channels, training programs, or comprehensive documentation beyond clinical publications are not explicitly provided for either tool in the available information.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	InVision Precision Cardiac Amyloid	EchoNext
Tool Name	InVision Precision Cardiac Amyloid	EchoNext
Company	InVision Medical Technology Corporation	Pathway Labs
Description	AI-powered software for echocardiography to detect cardiac amyloidosis, a life-threatening and often underdiagnosed disease, aiming for earlier detection and improved patient outcomes.	EchoNext is an FDA-cleared AI tool from Pathway Labs that analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension.
Key Features	AI-powered detection of cardiac amyloidosis; Evaluation of transthoracic echocardiogram studies (apical-4-chamber and parasternal-long-axis view videos); Aids clinicians in diagnosing and assessing patients with heart failure symptoms; Designed for earlier detection and reduction of misdiagnosis; Supports both AL and ATTR Cardiac Amyloidosis; Evidence-based AI algorithm, peer-reviewed and published in JAMA Cardiology; Integration into clinical workflow; Precise assessment of wall thickness in parasternal long axis view	AI-powered ECG analysis; Detection of hidden structural heart disease; Identifies heart failure risk; Screens for valve disease; Detects pulmonary hypertension indicators; Utilizes standard 12-lead ECGs; FDA-cleared technology; Non-invasive diagnostic support

Videos

Demos, reviews, and walkthroughs featuring InVision Precision Cardiac Amyloid and EchoNext.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools integrate into existing clinical workflows and EHR systems?

InVision Precision Cardiac Amyloid is designed as Software as a Medical Device (SaMD) for echocardiography labs, suggesting integration within the existing echo workflow. EchoNext is available through the OpenEvidence clinical decision support platform, which is used by many US clinicians, aiming to integrate its screening output into physicians' existing tools at the point of care.

What is the accuracy and sensitivity of each tool in detecting cardiac conditions?

InVision Precision Cardiac Amyloid focuses on AI-powered detection of cardiac amyloidosis from echocardiograms, with its algorithm peer-reviewed and published in JAMA Cardiology. EchoNext, analyzing standard ECGs, demonstrated high diagnostic accuracy for structural heart disease, with an AUROC of 85.2% and AUPRC of 78.5% in internal tests, and 78-80% in external validation. In a comparison, EchoNext achieved 77% accuracy in detecting structural heart problems from ECGs, outperforming cardiologists who had 64% accuracy.

For which specialties are these tools best suited, and what specific clinical contexts do they address?

InVision Precision Cardiac Amyloid is specifically designed for Cardiology and Radiology, aiding in the earlier detection and assessment of AL and ATTR Cardiac Amyloidosis in patients with heart failure symptoms. EchoNext is suited for Cardiology, Family Medicine, Hospital Medicine, and Internal Medicine, detecting hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension, from routine ECGs to identify patients who may need further cardiac ultrasound.

What is the typical learning curve for physicians and clinical staff using these AI tools?

While specific details on the learning curve for InVision Precision Cardiac Amyloid are not provided, its integration into existing echocardiography workflows suggests it aims for a streamlined adoption. EchoNext's availability through a widely used clinical decision support platform like OpenEvidence suggests an effort to make the tool accessible within familiar interfaces, potentially reducing the learning curve for physicians already using that platform.

Are there audit-trail features available to track how the AI tools are used and their impact on clinical decisions?

The provided information does not explicitly detail audit-trail features for either InVision Precision Cardiac Amyloid or EchoNext. However, robust audit logging for all system access is a common security measure in medical device quality management and information security management systems, which would be expected for such tools.

What considerations are important for multi-site rollout and ensuring consistent performance across different clinical settings?

For InVision Precision Cardiac Amyloid, multi-site rollout would involve integrating the SaMD into various echocardiography labs, requiring consistent workflow adoption and potentially standardized training. EchoNext has demonstrated consistent performance across diverse patient demographics, clinical contexts, and numerous hospitals, including external validation across multiple health systems, suggesting its suitability for multi-site deployment.